TrialLancet (London, England)2022

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jonathan P Piccini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.